fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.
暂无分享,去创建一个
Jane S. Paulsen | Stephen M. Rao | M. Benjamin | S. Hinton | D. Langbehn | J. Zimbelman | C. Leveroni | N. Reynolds | Michelle L. Benjamin
[1] R. C. Oldfield. The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.
[2] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[3] J. B. Martin,et al. Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.
[4] J. Talairach,et al. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .
[5] J. Penney,et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.
[6] Christopher A. Ross,et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.
[7] R. S. Williams,et al. Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.
[8] S. Folstein,et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.
[9] J. Penney,et al. Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.
[10] J A Obeso,et al. Temporal discrimination is abnormal in Parkinson's disease. , 1992, Brain : a journal of neurology.
[11] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[12] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[13] S. Folstein,et al. Selective Loss of [3H]Kainic Acid and [3H]AMPA Binding in Layer VI of Frontal Cortex in Huntington's Disease , 1994, Experimental Neurology.
[14] E. Siemers,et al. Cognitive scores in carriers of huntington's disease gene compared to noncarriers , 1995, Annals of neurology.
[15] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[16] R W Cox,et al. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. , 1996, Computers and biomedical research, an international journal.
[17] F. W. Cody,et al. The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson's disease. , 1996, Brain : a journal of neurology.
[18] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[19] J. Brandt,et al. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[20] D. Woodruff-Pak,et al. Huntington's disease and eyeblink classical conditioning: Normal learning but abnormal timing , 1996, Journal of the International Neuropsychological Society.
[21] D. Brooks,et al. Cortical control of movement in Huntington's disease. A PET activation study. , 1997, Brain : a journal of neurology.
[22] S. Shirato,et al. Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. , 1997, American journal of human genetics.
[23] A Weindl,et al. Central motor processing in Huntington's disease. A PET study. , 1997, Brain : a journal of neurology.
[24] M. Hayden,et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.
[25] A E Rosser,et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. , 1998, Brain : a journal of neurology.
[26] D. Harrington,et al. Temporal processing in the basal ganglia. , 1998, Neuropsychology.
[27] J. Brandt,et al. When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.
[28] J. Brandt,et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.
[29] T. Rammsayer,et al. Neuropharmacological Evidence for Different Timing Mechanisms in Humans , 1999, The Quarterly journal of experimental psychology. B, Comparative and physiological psychology.
[30] S. Hersch,et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.
[31] J L Lancaster,et al. Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.
[32] G. Pearlson,et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[33] A. Tobin,et al. Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.
[34] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[35] M. Schwaiger,et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. , 2001, Brain : a journal of neurology.
[36] Jane S. Paulsen,et al. Clinical markers of early disease in persons near onset of Huntington’s disease , 2001, Neurology.
[37] J. Cherry,et al. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. , 2001, Biochimica et biophysica acta.
[38] Armin Schnider,et al. Time estimation in Parkinson's disease: normal long duration estimation despite impaired short duration discrimination , 2001, Journal of Neurology.
[39] Stephen M. Rao,et al. The evolution of brain activation during temporal processing , 2001, Nature Neuroscience.
[40] S. Hersch,et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice , 2003, Journal of neurochemistry.
[41] Jane S. Paulsen,et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.
[42] R. Church,et al. The differential effects of haloperidol and methamphetamine on time estimation in the rat , 2004, Psychopharmacology.
[43] S. Folstein,et al. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study , 1992, Neuroradiology.